Inactive Instrument

Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Biotechnology & Medical Research

Ra Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019

May 09, 2019 at 04:30 pm IST

Ra Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, loss from operations was $20,089,000 against $16,724,000 a year ago. Net loss was $19,039,000 against $16,498,000 a year ago. Net loss per common share - basic and diluted was $0.45 against $0.61 a year ago.

Latest news about Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P TMI Index	03/20/03	CI
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Global BMI Index	03/20/03	CI
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Biotechnology Select Industry Index	03/20/03	CI
UCB SA completed the acquisition of Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.	02/20/02	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	27/20/27	CI
Ra Pharmaceuticals, Inc. Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	18/20/18	CI
Ra Pharmaceuticals, Inc. Announces Clearance of IND Application for the HEALEY ALS Platform Trial	22/20/22	CI
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	04/19/04	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	07/19/07	CI
UCB SA entered into an agreement to acquire Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and Ra Capital Management, LLC and others for $2.3 billion.	10/19/10	CI
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for GMG	02/19/02	CI
Certain Common Stock of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2019.	24/19/24	CI
Certain Stock Options of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2019.	24/19/24	CI
Certain Restricted Stock Units of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2019.	24/19/24	CI
Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck	21/19/21	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	07/19/07	CI
Transcript : Ra Pharmaceuticals, Inc. - Special Call	18/19/18
Ra Pharmaceuticals, Inc. Approves Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for the Year Ending December 31, 2019	13/19/13	CI
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy	04/19/04	CI
Transcript : Ra Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2019, May-21-2019 09:00 AM	21/19/21
Ra Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	09/19/09	CI
Peter Tuxen Bisgaard Not to Stand for Election to the Independent Director of Ra Pharmaceuticals, Inc	27/19/27	CI
Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study	09/19/09	CI
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) added to S&P Biotechnology Select Industry Index	18/19/18	CI
Certain Common Stock of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 11-MAR-2019.	11/19/11	CI

Chart Ra Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.26%	12TCr
REGENERON PHARMACEUTICALS, INC.	+13.04%	11TCr
BIONTECH SE	-13.56%	2.23TCr
ARGENX SE	-3.99%	2.16TCr
BEIGENE, LTD.	-5.62%	1.82TCr
WUXI APPTEC CO., LTD.	-39.93%	1.76TCr
NEUROCRINE BIOSCIENCES, INC.	+7.50%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+33.70%	1.24TCr
LEGEND BIOTECH CORPORATION	-28.33%	828.11Cr

Bio Therapeutic Drugs